推动科学发展,
提供治疗方法

about

关于我们

们是利用细菌功能来生产革命性新药物——活体生物药的先驱企业。

关于我们
developing-science

推动科学发展

我们开展了世界领先的研究,内容涵盖哮喘到癌症,从而研发具有类似药物功能的活体生物药,以治疗一系列疾病。

推动科学发展
delivering-therapies

提供治疗方法

我们的独特之处在于可以迅速将我们的研究成果用于对患者进行规范、安全且有效的治疗。

提供治疗方法

News

4D pharma (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announces that it has today conditionally placed with investors 3,797,469 new ordinary shares (the "Placing Shares"), through Zeus Capital Limited as broker to the Company, at a placing price of 790p per ordinary share to raise approximately £30 million before expenses (the "Placing").
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following clinical update on Blautix™, its proprietary live biotherapeutic for the treatment of Irritable Bowel Syndrome (IBS).
4D pharma completes target enrollment of 30 patients for Part A of its Phase I/II clinical trial of MRx-4DP0004 in patients with partly-controlled asthma. Following the completion of enrollment of Part A, 4D pharma expects to announce topline results from these patients in the second half of 2021. 4D pharma also announces the voluntary discontinuation of enrollment in the Phase II study of MRx-4DP0004 for the treatment of hospitalized patients with COVID-19 in the UK.

BACK TO TOP